Organigram Global is no longer arguing that Canadian recreational share alone can carry a listed cannabis equity. The latest quarter is the first clean look at a company that spent most of its cash to buy a German medical platform, then asked the market to treat the combined revenue line as proof the model works. Sanity Group, closed in mid-April, supplied the bulk of the sequential jump. The Canadian engine that was supposed to fund that ambition still carried the scars of a weak spring in vapes and infused pre-rolls.
The tension is whether Europe is a higher-margin medical overlay or a purchased top line sitting on a thinner treasury. Combined net revenue converted to about $74 million. Adjusted earnings before interest, tax, depreciation and amortization, the cash-earnings proxy that strips fair-value noise, converted to about $9 million. Reported profit was almost entirely a non-cash remeasurement of preferred shares held by British American Tobacco. Cash and short-term investments converted to about $8 million. Liquidity including undrawn credit converted to about $35 million.
The next several months resolve whether German medical volume plus a Canadian mix repair can turn fourth-quarter cash flow positive, as management still claims, before the earnout clock and the November hemp cutoff in the United States force another capital decision. The debate is no longer about who holds the leading Canadian share badge. It is about whether the platform generates cash, or only scale.